Terremoto Raises $108M to Pursue Development of Drugs Targeting AKT
Terremoto Biosciences announced a $108 million Series C round to accelerate its oral AKT‑targeting drug platform. The biotech currently has its lead candidate, TER‑2013, in a Phase 1 trial for solid tumors with specific genetic alterations, and plans to start clinical testing of TER‑4480 for hereditary hemorrhagic telangiectasia later this year. The new capital builds on a $175 million Series B in 2023 and a $75 million Series A in 2022, bringing total financing above $350 million. The company is led by Charles Baum, the former Mirati CEO whose firm was acquired for $4.8 billion.
Obsidian, Galera to Advance Cell Therapy Following Reverse Merger
Obsidian Therapeutics will go public on Nasdaq via a reverse merger with Galera Therapeutics, creating a combined entity focused on OBX-115, a tumor‑infiltrating lymphocyte (TIL) cell therapy. OBX-115 is in mid‑stage melanoma and early‑stage lung‑cancer trials and is designed to...
Connected Medical Devices: Smarter Care Starts Here
Connected medical devices (CMD) are becoming essential for gathering real‑world patient data and supporting decentralized clinical trials. Their integration—from wearable biosensors to continuous glucose monitors—requires dedicated service lines that manage calibration, storage, and data flow. Companies such as Marken are...
Rethinking Dermatology Trial Design for Late-Stage Success
Advances in immunology have spurred many new dermatology therapies, but late‑stage trial failures often stem from outdated trial designs. Traditional short‑term efficacy endpoints like PASI or EASI miss critical data on durability, patient‑reported outcomes, and long‑term safety. Experts advocate incorporating...
Oricell Closes a ‘Pre-IPO’ Megaround to Aim CAR-T at Solid Tumors
Oricell Therapeutics, a Shanghai‑based biotech, closed a pre‑IPO financing round of more than $110 million to accelerate its CAR‑T programs targeting solid tumors, starting with liver cancer. Its lead candidate, Ori‑C101, targets the GPC3 protein and has shown a 60% response...
Jeito Capital, Prominent Biotech Investor, Raises $1.2B for Next Fund
Jeito Capital announced the close of its Jeito II fund, raising €1 billion (about $1.2 billion) – the largest capital raise ever for an independent European biopharma fund. The fund will back 15‑20 clinical‑stage drugmakers, allocating up to €150 million ($162 million) per company across...
Terns Rebuffed a Higher Bid Before Selling to Merck
Terns Pharmaceuticals accepted Merck & Co.'s $53‑per‑share, $6.7 billion buyout, a price roughly 15% below an earlier $61 offer from an unnamed Party C. Party C’s proposal included a contingent $9‑per‑share payout tied to FDA approval of TERN‑701, but it withdrew after updated...
Gilead Continues M&A Surge with $3.1B Deal for ADC Specialist Tubulis
Gilead Sciences announced a deal to acquire German biotech Tubulis for $3.15 billion upfront, potentially rising to $5 billion with milestones. The purchase adds a next‑generation antibody‑drug conjugate (ADC) platform and two clinical candidates, TUB‑040 and TUB‑030, to Gilead’s oncology pipeline. This...
Sanofi Immune Drug Hopeful Posts Mixed Results in Mid-Stage Tests
Sanofi reported mixed Phase 2 results for its bispecific antibody lunsekig. The drug achieved its primary and key secondary endpoints in moderate‑to‑severe asthma and chronic rhinitis with nasal polyps, showing reduced exacerbations, improved lung function and smaller polyps. Conversely, lunsekig failed...
Hims & Hers Says Limited Data Stolen in Social Engineering Attack
Hims & Hers disclosed a sophisticated social‑engineering breach that compromised its third‑party customer‑service platform from February 4‑7, 2026. Hackers accessed service tickets, exposing customer names and email addresses, but the firm confirmed that electronic medical records and provider communications were untouched....
Under-the-Skin Tepezza Comparable to Infused Version in Key Study, Amgen Says
Amgen announced that its subcutaneous on‑body injector version of Tepezza, called Tepezza OBI, met both primary and key secondary endpoints in a late‑stage trial, showing 77% of patients achieved a meaningful reduction in eye bulging. The efficacy was comparable to...
Neurocrine to Acquire Prader-Will Drug in $2.9B Soleno Buyout
Neurocrine Biosciences agreed to acquire Soleno Therapeutics for $2.9 billion, securing the rare‑disease drug Vykat XR. Vykat generated $190 million in 2025 sales, including $92 million in the fourth quarter, but recent safety concerns and a slowdown in new patient starts have clouded its...
Perks Persuade Participants
Clinical trial sponsors are shifting from cash and checks to reloadable incentive cards to streamline participant compensation. Reloadable cards function like debit cards, allowing multiple reloads, real‑time tracking, and universal acceptance. InComm InCentives' Participant Perks Card offers a Visa‑branded, white‑label...
White House Seeks 12% Cut to HHS in 2027
The White House’s FY 2027 budget request calls for a 12.5% cut to the Department of Health and Human Services, slashing $15.8 billion from the agency’s discretionary budget. The proposal trims NIH funding by $5 billion, eliminates the National Institute on Minority Health...
Pfizer, BioNTech to Pause COVID Vaccine Study Due to Low Enrollment
Pfizer and BioNTech announced the suspension of a FDA‑mandated post‑marketing study of their COVID‑19 vaccine due to insufficient participant enrollment. The trial, aimed at 25,500 adults aged 50‑64, was designed to assess safety, immune response, and efficacy against infection. Companies...
